Trial: Prospective observational study in Chinese adults with relapsed/refractory DLBCL receiving glofitamab (with obinutuzumab pre‑treatment per label). Drugs and mechanisms: • Glofitamab: T‑cell–engaging bispecific IgG antibody (CD20xCD3). It binds CD20 on B cells and CD3 on T cells, forming an immune synapse that activates T cells to release perforin/granzymes and cytokines, killing malignant B cells. • Obinutuzumab: Glycoengineered type II anti‑CD20 monoclonal antibody (IgG1) given as pre‑treatment to debulk B cells and mitigate cytokine release syndrome, it induces direct cell death and ADCC of CD20+ B cells. Targets and pathways: CD20+ DLBCL B cells, CD3/TCR on T cells, pathways include T‑cell activation and cytotoxicity, and Fc‑mediated ADCC leading to B‑cell depletion.